HRP20110261T1 - Spojevi n-metilaminometilizoindola, pripravci koji ih sadrže i postupci njihove upotrebe - Google Patents
Spojevi n-metilaminometilizoindola, pripravci koji ih sadrže i postupci njihove upotrebe Download PDFInfo
- Publication number
- HRP20110261T1 HRP20110261T1 HR20110261T HRP20110261T HRP20110261T1 HR P20110261 T1 HRP20110261 T1 HR P20110261T1 HR 20110261 T HR20110261 T HR 20110261T HR P20110261 T HRP20110261 T HR P20110261T HR P20110261 T1 HRP20110261 T1 HR P20110261T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- optionally substituted
- alkoxy
- compound
- compound according
- Prior art date
Links
- GMFNCQYHNCIWFM-UHFFFAOYSA-N 1-isoindol-2-yl-N-methylmethanamine Chemical class C1=CC=CC2=CN(CNC)C=C21 GMFNCQYHNCIWFM-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 16
- 150000001875 compounds Chemical class 0.000 claims abstract 16
- 229910052736 halogen Chemical group 0.000 claims abstract 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 8
- 150000002367 halogens Chemical group 0.000 claims abstract 8
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims abstract 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract 5
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 239000012453 solvate Substances 0.000 claims abstract 4
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims abstract 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims abstract 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 208000034737 hemoglobinopathy Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84522706P | 2006-09-15 | 2006-09-15 | |
| PCT/US2007/020201 WO2008033567A1 (en) | 2006-09-15 | 2007-09-14 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110261T1 true HRP20110261T1 (hr) | 2011-05-31 |
Family
ID=38983295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110261T HRP20110261T1 (hr) | 2006-09-15 | 2011-04-12 | Spojevi n-metilaminometilizoindola, pripravci koji ih sadrže i postupci njihove upotrebe |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8648096B2 (el) |
| EP (1) | EP2076260B1 (el) |
| JP (1) | JP5567339B2 (el) |
| KR (1) | KR20090050107A (el) |
| CN (2) | CN103382197A (el) |
| AR (1) | AR062875A1 (el) |
| AT (1) | ATE502634T1 (el) |
| CA (1) | CA2663376C (el) |
| CL (1) | CL2007002670A1 (el) |
| CO (1) | CO6180446A2 (el) |
| CR (1) | CR10696A (el) |
| CY (1) | CY1112558T1 (el) |
| DE (1) | DE602007013436D1 (el) |
| DK (1) | DK2076260T3 (el) |
| ES (1) | ES2361584T3 (el) |
| HR (1) | HRP20110261T1 (el) |
| IL (1) | IL197566A0 (el) |
| MX (1) | MX2009002666A (el) |
| NI (1) | NI200900031A (el) |
| NZ (1) | NZ575689A (el) |
| PE (1) | PE20080832A1 (el) |
| PL (1) | PL2076260T3 (el) |
| PT (1) | PT2076260E (el) |
| RS (1) | RS51725B (el) |
| RU (1) | RU2009114159A (el) |
| SI (1) | SI2076260T1 (el) |
| TW (1) | TW200819435A (el) |
| UA (1) | UA95975C2 (el) |
| WO (1) | WO2008033567A1 (el) |
| ZA (1) | ZA200901852B (el) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006028964A1 (en) * | 2004-09-03 | 2006-03-16 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
| KR101342241B1 (ko) | 2005-06-30 | 2013-12-16 | 셀진 코포레이션 | 4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온 화합물의 제조 방법 |
| US8648096B2 (en) * | 2006-09-15 | 2014-02-11 | Celgene Corporation | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
| US20100160368A1 (en) * | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
| RU2527952C2 (ru) | 2008-10-29 | 2014-09-10 | Селджин Корпорейшн | Изоиндолиновые соединения для применения при лечении рака |
| SI2378876T1 (sl) | 2008-12-19 | 2019-05-31 | Medicis Pharmaceutical Corporation | Formulacije z nižjo dozirno jakostjo imikvimoda in kratki odmerni režimi za zdravljenje aktinične keratoze |
| AU2010274097B2 (en) | 2009-07-13 | 2016-06-16 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
| PT3202460T (pt) | 2010-02-11 | 2019-08-05 | Celgene Corp | Derivados arilmetoxi-indolina e composições que os compreendem e métodos para a sua utilização |
| WO2012135299A1 (en) | 2011-03-28 | 2012-10-04 | Deuteria Pharmaceuticals Inc | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| AU2014205043B2 (en) | 2013-01-14 | 2018-10-04 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| BR112015022785A2 (pt) | 2013-03-14 | 2017-07-18 | Epizyme Inc | composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt |
| WO2014152833A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| EP2970137A1 (en) | 2013-03-14 | 2016-01-20 | Epizyme, Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
| US9394258B2 (en) | 2013-03-14 | 2016-07-19 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9023883B2 (en) | 2013-03-14 | 2015-05-05 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
| WO2014153208A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9133189B2 (en) | 2013-03-14 | 2015-09-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9447079B2 (en) | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
| EP3363434A1 (en) | 2013-03-14 | 2018-08-22 | Epizyme Inc | Arginine methyltransferase inhibitors and uses thereof |
| EP2970134B1 (en) | 2013-03-14 | 2018-02-28 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| US20140314752A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
| UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| CA2957225A1 (en) | 2014-08-07 | 2016-02-11 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
| PL3214081T3 (pl) * | 2014-10-30 | 2021-04-06 | Kangpu Biopharmaceuticals, Ltd. | Pochodna izoindoliny, półprodukt, sposób wytwarzania, kompozycja farmaceutyczna i ich zastosowanie |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| WO2017040376A1 (en) * | 2015-08-31 | 2017-03-09 | The University Of Toledo | Potent phthalate inhibitors of aspartate n-acetyltransferase and selective aspartate pathway inhibitors |
| TWI728017B (zh) | 2015-12-15 | 2021-05-21 | 瑞典商阿斯特捷利康公司 | 異吲哚化合物、包含其之醫藥組成物及其用途 |
| EP3440082A1 (en) * | 2016-04-06 | 2019-02-13 | The Regents of The University of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| JP2019537585A (ja) | 2016-10-28 | 2019-12-26 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｅｚｈ２媒介性がんを治療するための組成物および方法 |
| WO2018106870A1 (en) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| JP2020524660A (ja) | 2017-06-14 | 2020-08-20 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド |
| EP3641762A4 (en) | 2017-06-20 | 2021-03-10 | C4 Therapeutics, Inc. | N / O BONDED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION |
| CN111278816B (zh) | 2017-09-04 | 2024-03-15 | C4医药公司 | 二氢喹啉酮 |
| WO2019043217A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROBENZIMIDAZOLONES |
| EP3679026A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| CA3092677A1 (en) * | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| CN112312904A (zh) | 2018-04-16 | 2021-02-02 | C4医药公司 | 螺环化合物 |
| HRP20231199T1 (hr) * | 2018-04-23 | 2024-01-19 | Celgene Corporation | Supstituirani spojevi 4-aminoizoindolin-1,3-diona i njihova upotreba za liječenje limfoma |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| CN115175903A (zh) * | 2019-10-21 | 2022-10-11 | 新基公司 | 治疗血液癌症的方法和2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮伴随生物标志物的用途 |
| AU2020369497A1 (en) | 2019-10-21 | 2022-05-19 | Celgene Corporation | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione |
| CN110746400B (zh) * | 2019-11-07 | 2021-12-17 | 郑州大学 | 一种靶向雄激素受体的荧光探针及其制备方法 |
| CA3208313A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| BR9908811A (pt) * | 1998-03-16 | 2000-12-05 | Celgene Corp | Composto, composição farmacêutica e seu uso no tratamento de mamìferos |
| US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CA2508171C (en) * | 2002-12-13 | 2012-08-28 | Cytopia Pty Ltd | Nicotinamide-based kinase inhibitors |
| US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| KR101342241B1 (ko) * | 2005-06-30 | 2013-12-16 | 셀진 코포레이션 | 4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온 화합물의 제조 방법 |
| US8648096B2 (en) * | 2006-09-15 | 2014-02-11 | Celgene Corporation | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
-
2007
- 2007-09-14 US US11/901,291 patent/US8648096B2/en active Active
- 2007-09-14 CL CL200702670A patent/CL2007002670A1/es unknown
- 2007-09-14 CN CN2013102182141A patent/CN103382197A/zh active Pending
- 2007-09-14 DE DE602007013436T patent/DE602007013436D1/de active Active
- 2007-09-14 WO PCT/US2007/020201 patent/WO2008033567A1/en active Application Filing
- 2007-09-14 UA UAA200903664A patent/UA95975C2/ru unknown
- 2007-09-14 EP EP07838415A patent/EP2076260B1/en active Active
- 2007-09-14 DK DK07838415.3T patent/DK2076260T3/da active
- 2007-09-14 TW TW096134612A patent/TW200819435A/zh unknown
- 2007-09-14 AT AT07838415T patent/ATE502634T1/de active
- 2007-09-14 PL PL07838415T patent/PL2076260T3/pl unknown
- 2007-09-14 KR KR1020097006986A patent/KR20090050107A/ko not_active Application Discontinuation
- 2007-09-14 PT PT07838415T patent/PT2076260E/pt unknown
- 2007-09-14 JP JP2009528337A patent/JP5567339B2/ja active Active
- 2007-09-14 SI SI200730569T patent/SI2076260T1/sl unknown
- 2007-09-14 RS RS20110258A patent/RS51725B/en unknown
- 2007-09-14 ES ES07838415T patent/ES2361584T3/es active Active
- 2007-09-14 ZA ZA200901852A patent/ZA200901852B/xx unknown
- 2007-09-14 RU RU2009114159/15A patent/RU2009114159A/ru not_active Application Discontinuation
- 2007-09-14 CN CNA2007800424312A patent/CN101534820A/zh active Pending
- 2007-09-14 CA CA2663376A patent/CA2663376C/en active Active
- 2007-09-14 NZ NZ575689A patent/NZ575689A/en not_active IP Right Cessation
- 2007-09-14 MX MX2009002666A patent/MX2009002666A/es active IP Right Grant
- 2007-09-17 PE PE2007001253A patent/PE20080832A1/es not_active Application Discontinuation
- 2007-09-17 AR ARP070104112A patent/AR062875A1/es unknown
-
2009
- 2009-03-12 IL IL197566A patent/IL197566A0/en unknown
- 2009-03-13 NI NI200900031A patent/NI200900031A/es unknown
- 2009-03-30 CR CR10696A patent/CR10696A/es not_active Application Discontinuation
- 2009-04-03 CO CO09034806A patent/CO6180446A2/es not_active Application Discontinuation
-
2011
- 2011-04-12 HR HR20110261T patent/HRP20110261T1/hr unknown
- 2011-05-20 CY CY20111100500T patent/CY1112558T1/el unknown
-
2013
- 2013-12-30 US US14/144,292 patent/US20140113935A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110261T1 (hr) | Spojevi n-metilaminometilizoindola, pripravci koji ih sadrže i postupci njihove upotrebe | |
| JP2010503688A5 (el) | ||
| HRP20120447T1 (hr) | 5-supstituirani derivati kinazolinona kao protutumorska sredstva | |
| RU2009111273A (ru) | 5-замещенные изоиндолиновые соединения | |
| MA28706B1 (fr) | Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques | |
| EP2474524A3 (en) | Ligands for imaging cardiac innervation | |
| MY145465A (en) | Diaminopyrimidines as p2x3 and p2x2/3 antagonists. | |
| BRPI0507497A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, e, métodos para prevenir e/ou tratar distúrbios mediados por receptor de mglur5 e para inibir a ativação de receptores de mglur5 | |
| FR2903107B1 (fr) | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique | |
| JP2010540525A5 (el) | ||
| RU2007134380A (ru) | Антибактериальные производные пиперидина | |
| WO2006069155A3 (en) | Inhibitors of protein arginine methyl transferases | |
| BRPI0513843A (pt) | composto ou um sal ou solvato ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, forma de dosagem, uso de um composto, e, sal de cloridrato | |
| EA200800781A1 (ru) | АМИДНЫЕ И КАРБАМАТНЫЕ ПРОИЗВОДНЫЕ АЛКИЛЗАМЕЩЕННЫХ N-[4-(4-АМИНО-1Н-ИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)БУТИЛ]МЕТАНСУЛЬФОНАМИДОВ И СПОСОБЫ | |
| WO2005115361A3 (en) | Androgen receptor modulators and method of treating disease using the same | |
| JP2003500442A5 (el) | ||
| MXPA05013587A (es) | Agentes terapeuticos utiles para el tratamiento del dolor. | |
| RU99101081A (ru) | Режим введения ингибиторов н+, к+-атфазы | |
| CY1109962T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας | |
| DK2040703T3 (da) | Derivater af 2-benzoylimidazopyridiner, fremstilling deraf og terapeutisk anvendelse deraf | |
| HRP20110344T1 (hr) | Derivati dihidropiridina | |
| DE602004002394D1 (de) | (3-ä3-'(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINOÜ-PROPOXYü-PHENYL)-ESSIGSÄURE UND VERWANDTE VERBINDUNGEN ALS MODULATOREN VON PPARS UND VERFAHREN ZUR BEHANDLUNG VON STOFFWECHSELSTÖRUNGEN | |
| EA200601249A1 (ru) | Пиперазины, пригодные для лечения боли | |
| EA200801447A1 (ru) | Фармацевтическая композиция | |
| JP2014504648A5 (el) |